Human PAI-1 (stable mutant form)

$695$1,140

Clear
SKU: CPAI Categories: ,

Product Description

Human PAI-1 (stable mutant form)

The human form of PAI-1 contains the following four mutations: K154T, Q319L, M354I and N150H. These mutations combine to confer great stability to the otherwise labile molecule essentially locking in into the active conformation. It is an ideal choice for in vivo studies.

Gene ID: 5054
Swiss-Prot/UniProt ID: P05121

View sample datasheet
View sample certificate of analysis
View material safety data sheet
Ask a question about this product

Additional Information

Purity

Source

Molecular Weight

Activity

Extinction Coefficient

Species

Storage

Shipping Conditions

Expiration

Form

Buffer

Sample Size

Sample Concentration

Sample Volume

Gene Name

Gene ID

UniProt ID

1. Minor KH, Schar CR, Blouse GE et-al. A mechanism for assembly of complexes of vitronectin and plasminogen activator inhibitor-1 from sedimentation velocity analysis. J. Biol. Chem. 2005;280 (31): 28711-20. doi:10.1074/jbc.M500478200Free text at pubmedPubmed citation

2. Crandall DL, Quinet EM, El ayachi S et-al. Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler. Thromb. Vasc. Biol. 2006;26 (10): 2209-15. doi:10.1161/01.ATV.0000235605.51400.9dPubmed citation

3. Horowitz JC, Rogers DS, Simon RH et-al. Plasminogen activation induced pericellular fibronectin proteolysis promotes fibroblast apoptosis. Am. J. Respir. Cell Mol. Biol. 2008;38 (1): 78-87. doi:10.1165/rcmb.2007-0174OCFree text at pubmedPubmed citation

4. Zhang Y, Zhou ZH, Bugge TH et-al. Urokinase-type plasminogen activator stimulation of monocyte matrix metalloproteinase-1 production is mediated by plasmin-dependent signaling through annexin A2 and inhibited by inactive plasmin. J. Immunol. 2007;179 (5): 3297-304. J. Immunol. (link)Pubmed citation

5. Schar CR, Blouse GE, Minor KH et-al. A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity. J. Biol. Chem. 2008;283 (16): 10297-309. doi:10.1074/jbc.M708017200Free text at pubmedPubmed citation

6. Yang D, Nemkul N, Shereen A et-al. Therapeutic administration of plasminogen activator inhibitor-1 prevents hypoxic-ischemic brain injury in newborns. J. Neurosci. 2009;29 (27): 8669-74. doi:10.1523/JNEUROSCI.1117-09.2009Pubmed citation

7. Yang D, Sun YY, Nemkul N et-al. Plasminogen activator inhibitor-1 mitigates brain injury in a rat model of infection-sensitized neonatal hypoxia-ischemia. Cereb. Cortex. 2013;23 (5): 1218-29. doi:10.1093/cercor/bhs115Free text at pubmedPubmed citation

8. Fang H, Placencio VR, Declerck YA. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. J. Natl. Cancer Inst. 2012;104 (19): 1470-84. doi:10.1093/jnci/djs377Free text at pubmedPubmed citation

9. Courey AJ, Horowitz JC, Kim KK et-al. The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice. Blood. 2011;118 (8): 2313-21. doi:10.1182/blood-2010-12-324574Free text at pubmedPubmed citation

10. Yang D, Sun YY, Lin X et-al. Taming neonatal hypoxic-ischemic brain injury by intranasal delivery of plasminogen activator inhibitor-1. Stroke. 2013;44 (9): 2623-7. doi:10.1161/STROKEAHA.113.001233Pubmed citation

11. Simone TM, Higgins SP, Archambeault J, et al. A small molecule PAI-1 functional inhibitor attenuates neointimal hyperplasia and vascular smooth muscle cell survival by promoting PAI-1 cleavage. Cell Signal. 2015;27(5):923-33. link to article

12. Damare J, Brandal S, Fortenberry YM. Inhibition of PAI-1 antiproteolytic activity against tPA by RNA aptamers. Nucleic Acid Ther. 2014;24(4):239-49. link to article

13. Yang D, Kuan CY. Anti-tissue plasminogen activator (tPA) as an effective therapy of neonatal hypoxia-ischemia with and without inflammation. CNS Neurosci Ther. 2015;21(4):367-73. link to article

14. Dinarvand p, Hassanian SM, Weiler H, Rezaie AR. Activated Protein C Prevents Post surgical Adhesion Band Formation. Link to article

15. Lee JA, Characterisation of SerpinB2 as a stress response modulator. University of Wollongong Thesis Collection. 2015

16. Eren M, Place AT, Thomas PM, Flevaris P, Miyata T, Vaughan DE. PAI-1 is a critical regulator of FGF23 homeostasis. Sci Adv. 2017;3(9):e1603259. Link to article